Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects

Journal of Clinical Pharmacology

Volumn 50, Issue 10, 2010, Pages 1211-1216

  Patel, Chirag G ^a   Zhang, Jenny ^a   Li Li, ^a   Gooding, Lara ^a   Croop, Robert ^a   Tong Li, ^a   Boulton, David W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

food effect; high fat meal; Saxagliptin

Indexed keywords

CYTOCHROME P450; GLUCAGON LIKE PEPTIDE 1; GLYCOPROTEIN P; SAXAGLIPTIN;

ADULT; ARTICLE; BODY MASS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INSULIN RELEASE; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; SINGLE DRUG DOSE; TREATMENT FAILURE; WEIGHT GAIN;

ADAMANTANE; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DIETARY FATS; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE;

EID: 77954072107     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009360532     Document Type: Article

References (25)

1. Zander M., Madsbad S., Deacon CF, Holst JJ The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia. 2006 ; 49: 369-374.
2. Deacon CF Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2007 ; 9 (suppl 1). 23-31.
3. Data on file. Bristol-Myers Squibb Pharmaceutical Research Institute ; 2006.
4. Data on file. Bristol-Myers Squibb Pharmaceutical Research Institute ; 2003.
5. Data on file. Bristol-Myers Squibb Pharmaceutical Research Institute ; 2007.
6. Genser D. Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab. 2008 ; 52 (suppl 1). 29-32.
7. Poiger H., Schlatter C. Compensation of dietary induced reduction of tetracycline absorption by simultaneous administration of EDTA. Eur J Clin Pharmacol. 1978 ; 14: 129-131.
8. Welling PG Effects of food on drug absorption. Annu Rev Nutr. 1996 ; 16: 383-415.
9. Data on file. Bristol-Myers Squibb Pharmaceutical Research Institute ; 2005.
10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Food Effect Bioavailability and Fed Bioequivalence Studies (Draft Guidance) December 2002. Silver Spring, Md: U.S. Food and Drug Administration ; 2002.
11. Quantitative determination of BMS-477118 and BMS-510849 in human plasma by LC/MS/MS Using enhanced chromatography. Data on file. Bristol-Myers Squibb Research and Development ; 2007.
12. Bornemann LD, Crews T., Chen SS, Twardak S., Patel IH Influence of food on midazolam absorption. J Clin Pharmacol. 1986 ; 26: 55-59.
13. Yun HY, Joo Lee E., Youn Chung S., et al. The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule. Clin Pharmacokinet. 2006 ; 45: 425-432.
14. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact. 2004 ; 20: 195-217.
15. McLean AJ, Isbister C., Bobik A., Dudley FJ Reduction of first-pass hepatic clearance of propranolol by food. Clin Pharmacol Ther. 1981 ; 30: 31-34. (Pubitemid 11033785)
16. Melander A., Lalka D., McLean A. Influence of food on the presystemic metabolism of drugs. Pharmacol Ther. 1988 ; 38: 253-267.
17. Mertens-Talcott SU, Zadezensky I., De Castro WV, Derendorf H., Butterweck V. Grapefruit-drug interactions: can interactions with drugs be avoided ? J Clin Pharmacol. 2006 ; 46: 1390-1416.
18. Mao CC, Jacobson ED Intestinal absorption and blood flow. Am J Clin Nutr. 1970 ; 23: 820-823.
19. Brandt JL, Castleman L., Ruskin HD, Greenwald J., Kelly JJ Jr. The effect of oral protein and glucose feeding of splanchnic blood flow and oxygen utilization in normal and cirrhotic subjects. J Clin Invest. 1955 ; 34 (7, part 1). 1017-1025.
20. McLean AJ, McNamara PJ, duSouich P., Gibaldi M., Lalka D. Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther. 1978 ; 24: 5-10.
21. Toothaker RD, Welling PG The effect of food on drug bioavailability. Annu Rev Pharmacol Toxicol. 1980 ; 20: 173-199.
22. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company ; Wilmington, DE: AstraZeneca Pharmaceuticals LP ; July 2009.
23. Drucker DJ, Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 ; 368: 1696-1705.
24. Johnson JA, Herring VL, Wolfe MS, Relling MV CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther. 2000 ; 294: 1099-1105.
25. Perrier D., Gibaldi M. Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther. 1974 ; 191: 17-24.